To the Editor: The article by Hull and his colleagues1 presents some interesting data and raises questions about the conclusions drawn. The ineffectiveness of low-dose heparin in that trial may have been related to the primary treatment regimen and may not mean that such therapy is without merit. This possibility is discussed in the editorial by Wessler and Gitel.2 As they pointed out, continuous infusion of intravenous heparin is associated with a decrease in antithrombin III.3 Since heparin acts as a cofactor and greatly accelerates the rate at which antithrombin III inhibits thrombin,4 it seems logical to assume that the. No extract is available for articles shorter than 400 words.
ASJC Scopus subject areas